Baldwin D S
Department of Mental Health, University of Southampton, UK.
Int Clin Psychopharmacol. 2000 Jul;15 Suppl 1:S19-24. doi: 10.1097/00004850-200007001-00005.
Paroxetine is a selective serotonin reuptake inhibitor (SSRI) with proven efficacy in the treatment of depression, panic disorder and obsessive-compulsive disorder. Evidence that paroxetine may be effective in social anxiety disorder (social phobia) first arose from open-label studies. More recently, three multicentre, randomized, placebo-controlled trials have been performed, each lasting 12 weeks, to assess the efficacy and tolerability of paroxetine in the treatment of social anxiety disorder, and these studies are reviewed here. The data from all three studies consistently demonstrated that paroxetine was effective in reducing both the symptoms of anxiety and the disability and impairment of social anxiety disorder. Paroxetine performed significantly better than placebo on all primary (Liebowitz Social Anxiety Scale, Clinical Global Impression) and secondary (Social Avoidance and Distress Scale, Sheehan Disability Scale) outcome measures. Adverse events were restricted to those already known to be associated with SSRIs, no serious adverse events associated with medication were experienced, and the numbers withdrawing from the studies were not significantly different in the paroxetine and control groups. Taken together, these studies confirm that paroxetine is an effective and well tolerated treatment for patients with social anxiety disorder.
帕罗西汀是一种选择性5-羟色胺再摄取抑制剂(SSRI),已证实其在治疗抑郁症、惊恐障碍和强迫症方面具有疗效。帕罗西汀可能对社交焦虑障碍(社交恐惧症)有效的证据最初来自开放标签研究。最近,进行了三项多中心、随机、安慰剂对照试验,每项试验持续12周,以评估帕罗西汀治疗社交焦虑障碍的疗效和耐受性,本文将对这些研究进行综述。所有三项研究的数据一致表明,帕罗西汀在减轻焦虑症状以及社交焦虑障碍的功能障碍和损害方面均有效。在所有主要(利博维茨社交焦虑量表、临床总体印象)和次要(社交回避及苦恼量表、希恩功能障碍量表)结局指标上,帕罗西汀的表现均显著优于安慰剂。不良事件仅限于那些已知与SSRI相关的事件,未出现与药物相关的严重不良事件,且帕罗西汀组和对照组退出研究的人数无显著差异。综上所述,这些研究证实帕罗西汀是治疗社交焦虑障碍患者的一种有效且耐受性良好的药物。